With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.
- New treatment for rabies advances after successful phase 1 trial in IndiaTue, 14 Sep 2010, 12:50:05 EDT
- First human gets new antibody aimed at rabies virusWed, 30 Sep 2009, 14:25:38 EDT
- Genetically modified tobacco plants produce antibodies to treat rabiesFri, 1 Feb 2013, 13:23:31 EST
- First human gets new antibody aimed at hepatitis C virusThu, 6 Aug 2009, 11:36:22 EDT
- New treatment shown to reduce recurrence of debilitating diarrheaWed, 20 Jan 2010, 18:01:42 EST